<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00879645</url>
  </required_header>
  <id_info>
    <org_study_id>S103</org_study_id>
    <nct_id>NCT00879645</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function</brief_title>
  <official_title>A Phase I Study to Assess the Pharmacokinetics of IK-1001 (Sodium Sulfide) in Subjects With Impaired Renal Function Following a Continuous 3-hour Intravenous Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study to assess the pharmacokinetics (PK) of IK-1001 (sodium sulfide) in
      healthy volunteers as well as in subjects with varying degrees of impaired renal function. A
      total of 28 subjects will be enrolled into the study over a 6 month period. There will be 4
      cohorts. The first cohort will consist of subjects with mild renal impairment, the fourth
      cohort will be subjects with intermediate renal impairment and the third cohort will be
      subjects with severe renal impairment and the second cohort will consist of normal healthy
      subjects. All subjects will receive the study drug for 3 hours as a single intravenous (IV)
      infusion and will be followed over a 7 day period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 pharmacokinetic study to assess the pharmacokinetics of IK-1001 in healthy
      volunteers as well as subjects with varying degrees of impaired renal function following a
      single intravenous infusion.

      A total of 28 subjects will be enrolled into the study, including 6 normal subjects
      (Creatinine Clearance (CrCL) &gt; 80 mL/min), 9 subjects with mild impairment (CrCL ≥ 50 to &lt; 80
      mL/min), 6 subjects with intermediate impairment (≥ 30 to &lt; 50 mL/min) and 7 subjects with
      severe impairment (CrCL &lt; 30 mL/min).

      Mild, moderate and normal healthy subjects will receive IK-1001 as a single IV infusion for 3
      hours at 1.5 mg/kg/hr. Blood, plasma, urine and exhaled air will be collected from each
      subject over 48 hours and at follow-up visit (Day 7), to evaluate pharmacokinetics of
      Hydrogen Sulfide (H2S) (exhaled air), IK-1001 (blood) and thiosulfate in plasma and urine.
      Severe subjects will receive IK-1001 as a single IV infusion for 3 hours at 1.0 mg/kg/hr.

      For each dosing cohort, the study will consist of a screening visit (Days -28 to -1), a
      treatment visit (Day 0 (check-in) to Day 3), and a follow-up (exit) visit day 7 (+/- 2 days).

      Study subjects will be enrolled to one of 4 cohorts and all will receive investigational
      product at the given dose level. The subjects will be considered to be enrolled in the study
      at randomization.

      IK-1001 will be administered by a healthcare professional intravenously over 3 hours using an
      infusion pump. Dosage of IK-1001 will be administered on actual body weight basis, according
      to cohort assignment and using the subject's body weight determined on Day -1. After the end
      of the initial 3-hour study period, subjects will be observed for an additional 45 hour
      period before discharge from the unit.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    unable to develop a rapid &amp; reliable assay to detect sulfide concentrations
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thiosulfate in Plasma</measure>
    <time_frame>8 hours after treatment</time_frame>
    <description>Total concentration of thiosulfate in plasma was measured through pharmacokinetic blood sampling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thiosulfate in Urine</measure>
    <time_frame>48 hours after treatment</time_frame>
    <description>Total concentration of thiosulfate in urine was measure through pharmacokinetic urine collection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sodium Sulfide in Blood</measure>
    <time_frame>8 hours after treatment</time_frame>
    <description>Total concentration of sodium sulfide in blood was measured through pharmacokinetic blood sampling.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis</measure>
    <time_frame>Baseline, Days 1, 2, and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology</measure>
    <time_frame>Baseline, Days 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>Baseline, Day 0 through 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation Factors</measure>
    <time_frame>Baseline, Day 1, 2, and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemistry</measure>
    <time_frame>Baseline, Days 1, 2, and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Clearance</measure>
    <time_frame>Baseline, Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exhaled Sulfide</measure>
    <time_frame>Baseline through day 2</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Sodium Sulfide - Mild Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild renal impairment (RI) Cohort administered 1.5 mg/kg/hr infusion of Sodium sulfide intravenously for 3 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Sulfide - Healthy Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Sulfide - Moderate Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate RI cohort received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Sulfide - Severe Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe RI cohort received sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Sulfide</intervention_name>
    <description>Sodium sulfide administered intravenously at 1.5 mg/kg/hr for 3 hours</description>
    <arm_group_label>Sodium Sulfide - Mild Cohort</arm_group_label>
    <other_name>IK-1001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Sulfide</intervention_name>
    <description>Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours</description>
    <arm_group_label>Sodium Sulfide - Healthy Cohort</arm_group_label>
    <other_name>IK-1001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Sulfide</intervention_name>
    <description>Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours</description>
    <arm_group_label>Sodium Sulfide - Moderate Cohort</arm_group_label>
    <other_name>IK-1001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Sulfide</intervention_name>
    <description>Sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours</description>
    <arm_group_label>Sodium Sulfide - Severe Cohort</arm_group_label>
    <other_name>IK-1001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. For normal subjects arm (CrCL &gt; 80 ml/min): Healthy male and female subjects age 18 to
             70 years of age inclusive. Pregnant women are excluded and women of child-bearing
             potential must agree to the use of medically reliable contraceptive methods for the
             duration of the study and for 30 days after study.

             For renally impaired arm: Male and female - pregnant women are excluded and women of
             child-bearing potential must agree to the use of medically reliable contraceptive
             methods for the duration of the study and for 30 days after study. Subjects with mild,
             moderate and severe renal function aged between 18 to 70 years old

          2. Body mass index (BMI) within the range of 18 to 40 kg/m2

          3. Electrocardiogram (ECG) recording without clinically relevant abnormalities

          4. Having had no febrile or infectious disease for at least seven days prior to dosing of
             study drug

          5. Able to communicate well with the study staff and to understand and comply with the
             requirements of the study, understand and sign the written informed consent

        Exclusion Criteria:

          1. High risk patients who may need an urgent dialysis during clinical conduct portion of
             the study (from Day -1 until last PK sampling on Day 7)

          2. All smokers.

          3. More than moderate alcohol consumption (&gt;35 g ethanol regularly or &gt; 2 drinks per day
             )

          4. Any history of alcohol or drug abuse

          5. Any active physical or psychiatric disease, acute or chronic

          6. Any clinically relevant history of drug hypersensitivity, asthma, urticaria or other
             severe allergic diathesis

          7. Pregnant or nursing women

          8. Blood donation within 30 days

          9. Participation in any clinical study within 30 days prior to the treatment phase of
             this study

         10. Lab values outside of reference range and clinically relevant liver function tests
             (AST, ALT, gamma-GT)

         11. Positive tests for HIV antibodies, Hepatitis B-virus surface antigen (HBsAg),
             Anti-Hepatitis C-virus antibodies (Anti-HCV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brahm Goldstein, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2009</study_first_submitted>
  <study_first_submitted_qc>April 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2009</study_first_posted>
  <results_first_submitted>October 7, 2010</results_first_submitted>
  <results_first_submitted_qc>October 7, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2010</results_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Impairment</keyword>
  <keyword>Renal Disease</keyword>
  <keyword>Sodium Sulfide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sodium Sulfide - Mild Cohort</title>
          <description>Mild renal impairment (RI) Cohort administered 1.5 mg/kg/hr infusion of Sodium sulfide intravenously for 3 hours.</description>
        </group>
        <group group_id="P2">
          <title>Sodium Sulfide - Healthy Cohort</title>
          <description>Healthy subjects received soduim sufide intravenously at 1.5 mg/kg/hr for 3 hours</description>
        </group>
        <group group_id="P3">
          <title>Sodium Sulfide - Moderate Cohort</title>
          <description>Moderate RI cohort received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours</description>
        </group>
        <group group_id="P4">
          <title>Sodium Sulfide - Severe Cohort</title>
          <description>Severe RI cohort received sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sodium Sulfide - Mild Cohort</title>
          <description>Mild renal impairment (RI) Cohort administered 1.5 mg/kg/hr infusion of Sodium sulfide intravenously for 3 hours.</description>
        </group>
        <group group_id="B2">
          <title>Sodium Sulfide - Healthy Cohort</title>
          <description>Healthy subjects received soduim sufide intravenously at 1.5 mg/kg/hr for 3 hours</description>
        </group>
        <group group_id="B3">
          <title>Sodium Sulfide - Moderate Cohort</title>
          <description>Moderate RI cohort received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours</description>
        </group>
        <group group_id="B4">
          <title>Sodium Sulfide - Severe Cohort</title>
          <description>Severe RI cohort received sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.3" spread="7.41"/>
                    <measurement group_id="B2" value="56.1" spread="14.69"/>
                    <measurement group_id="B3" value="60.6" spread="7.91"/>
                    <measurement group_id="B4" value="48.9" spread="11.96"/>
                    <measurement group_id="B5" value="55.3" spread="10.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Thiosulfate in Plasma</title>
        <description>Total concentration of thiosulfate in plasma was measured through pharmacokinetic blood sampling.</description>
        <time_frame>8 hours after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sodium Sulfide - Mild Cohort</title>
            <description>Mild renal impairment (RI) Cohort administered 1.5 mg/kg/hr infusion of Sodium sulfide intravenously for 3 hours.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Sulfide - Healthy Cohort</title>
            <description>Healthy subjects received soduim sufide intravenously at 1.5 mg/kg/hr for 3 hours</description>
          </group>
          <group group_id="O3">
            <title>Sodium Sulfide - Moderate Cohort</title>
            <description>Moderate RI cohort received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours</description>
          </group>
          <group group_id="O4">
            <title>Sodium Sulfide - Severe Cohort</title>
            <description>Severe RI cohort received sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Thiosulfate in Plasma</title>
          <description>Total concentration of thiosulfate in plasma was measured through pharmacokinetic blood sampling.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.4" spread="57.83"/>
                    <measurement group_id="O2" value="199.6" spread="100.74"/>
                    <measurement group_id="O3" value="199.1" spread="60.32"/>
                    <measurement group_id="O4" value="190.1" spread="36.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Thiosulfate in Urine</title>
        <description>Total concentration of thiosulfate in urine was measure through pharmacokinetic urine collection</description>
        <time_frame>48 hours after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sodium Sulfide - Mild Cohort</title>
            <description>Mild renal impairment (RI) Cohort administered 1.5 mg/kg/hr infusion of Sodium sulfide intravenously for 3 hours.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Sulfide - Healthy Cohort</title>
            <description>Healthy subjects received soduim sufide intravenously at 1.5 mg/kg/hr for 3 hours</description>
          </group>
          <group group_id="O3">
            <title>Sodium Sulfide - Moderate Cohort</title>
            <description>Moderate RI cohort received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours</description>
          </group>
          <group group_id="O4">
            <title>Sodium Sulfide - Severe Cohort</title>
            <description>Severe RI cohort received sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Thiosulfate in Urine</title>
          <description>Total concentration of thiosulfate in urine was measure through pharmacokinetic urine collection</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1805.5" spread="552.00"/>
                    <measurement group_id="O2" value="2137.7" spread="688.83"/>
                    <measurement group_id="O3" value="1114.3" spread="720.79"/>
                    <measurement group_id="O4" value="603.8" spread="433.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sodium Sulfide in Blood</title>
        <description>Total concentration of sodium sulfide in blood was measured through pharmacokinetic blood sampling.</description>
        <time_frame>8 hours after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sodium Sulfide - Mild Cohort</title>
            <description>Mild renal impairment (RI) Cohort administered 1.5 mg/kg/hr infusion of Sodium sulfide intravenously for 3 hours.</description>
          </group>
          <group group_id="O2">
            <title>Sodium Sulfide - Healthy Cohort</title>
            <description>Healthy subjects received soduim sufide intravenously at 1.5 mg/kg/hr for 3 hours</description>
          </group>
          <group group_id="O3">
            <title>Sodium Sulfide - Moderate Cohort</title>
            <description>Moderate RI cohort received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours</description>
          </group>
          <group group_id="O4">
            <title>Sodium Sulfide - Severe Cohort</title>
            <description>Severe RI cohort received sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Sodium Sulfide in Blood</title>
          <description>Total concentration of sodium sulfide in blood was measured through pharmacokinetic blood sampling.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2" spread="12.23"/>
                    <measurement group_id="O2" value="49.6" spread="14.58"/>
                    <measurement group_id="O3" value="49.8" spread="17.23"/>
                    <measurement group_id="O4" value="42.9" spread="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs</title>
        <time_frame>Study duration</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinalysis</title>
        <time_frame>Baseline, Days 1, 2, and 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematology</title>
        <time_frame>Baseline, Days 1 and 2</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-lead ECG</title>
        <time_frame>Baseline, Day 0 through 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Coagulation Factors</title>
        <time_frame>Baseline, Day 1, 2, and 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemistry</title>
        <time_frame>Baseline, Days 1, 2, and 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine Clearance</title>
        <time_frame>Baseline, Day 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exhaled Sulfide</title>
        <time_frame>Baseline through day 2</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sodium Sulfide - Mild Cohort</title>
          <description>Mild renal impairment (RI) Cohort administered 1.5 mg/kg/hr infusion of Sodium sulfide intravenously for 3 hours.</description>
        </group>
        <group group_id="E2">
          <title>Sodium Sulfide - Healthy Cohort</title>
          <description>Healthy subjects received soduim sufide intravenously at 1.5 mg/kg/hr for 3 hours</description>
        </group>
        <group group_id="E3">
          <title>Sodium Sulfide - Moderate Cohort</title>
          <description>Moderate RI cohort received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours</description>
        </group>
        <group group_id="E4">
          <title>Sodium Sulfide - Severe Cohort</title>
          <description>Severe RI cohort received sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion Site Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Infusion Site Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Infusion Site Phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Infusion Site Anaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Application Site Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Application Site Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Infusion Site Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lawrence Hill</name_or_title>
      <organization>Mallinckrodt</organization>
      <phone>908-238-6370</phone>
      <email>lawrence.hill@mallinckrodt.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

